

**Klachkova, Anastasiya (CSC/SCC)**

---

**From:** Dunn Kathleen (NHQ-AC)  
**Sent:** March 12, 2021 9:17 AM  
**To:** Boudreau Harold (NHQ-AC)  
**Cc:** Clement Chris (NHQ-AC); Wheatley Jennifer (NHQ-AC)  
**Subject:** FW: The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID-19 infection - PubMed

Harold

As mentioned

The WHO Clinical trials (RECOVERY) - has several targeted aspects, including use of anticoagulants - aspirin is one of the therapeutics being studied The slides from the presentation a couple of weeks ago, is yet to be shared. WHO / Global Research Network likely will publish early findings

Here is a link (Pubmed) for one study.

The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID-...

<https://pubmed.ncbi.nlm.nih.gov/33621437/>

Aspirin use is associated with better outcomes among COVID-19 positive patients.

Hypothesis that aspirin use for primary cardiovascular disease prevention might have a protective effect on COVID-19 susceptibility and disease duration.